AI Article Synopsis
- Diabetic macular edema (DME) is a common issue linked to diabetic retinopathy that often requires long-term treatment options like the fluocinolone acetonide (FAc) implant.
- Although the FAc implant can be effective and is generally well tolerated, it may cause side effects such as ocular hypertension and cataracts, necessitating caution when prescribing.
- The review aims to give clinicians a comprehensive understanding of the FAc implant, helping them make informed decisions and effectively implement its use in DME management.
Article Abstract
Diabetic macular edema (DME) is a common complication of diabetic retinopathy. Treatment with intravitreal injections is effective in most cases but is associated with a high therapeutic burden for patients. This implies the need for long-term treatments, such as the fluocinolone acetonide (FAc) implant. A review of basic science, pharmacology, and clinical data was conducted to provide a state-of-the-art view of the FAc implant in 2024. Although generally well tolerated, the FAc implant has been associated with ocular hypertension and cataract, and caution should be advised to the patients in this regard. By synthesizing information across these domains, a comprehensive evaluation can be attained, facilitating informed decision-making regarding the use of the FAc implant in the management of DME. The main objective of this review is to provide clinicians with guidelines on how to introduce and use the FAc implant in a patient with DME.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11435168 | PMC |
| http://dx.doi.org/10.3390/pharmaceutics16091183 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!